{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T21:24:48Z","timestamp":1760909088071,"version":"3.37.3"},"reference-count":15,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2017,11,28]],"date-time":"2017-11-28T00:00:00Z","timestamp":1511827200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100006436","name":"Celgene","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006436","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Br J Haematol"],"published-print":{"date-parts":[[2018,1]]},"abstract":"Summary<\/jats:title>In the mantle cell lymphoma (MCL<\/jats:styled-content>)\u2010002 study, lenalidomide demonstrated significantly improved median progression\u2010free survival (PFS<\/jats:styled-content>) compared with investigator's choice (IC<\/jats:styled-content>) in patients with relapsed\/refractory MCL<\/jats:styled-content>. Here we present the long\u2010term follow\u2010up data and results of preplanned subgroup exploratory analyses from MCL<\/jats:styled-content>\u2010002 to evaluate the potential impact of demographic factors, baseline clinical characteristics and prior therapies on PFS<\/jats:styled-content>. In MCL<\/jats:styled-content>\u2010002, patients with relapsed\/refractory MCL<\/jats:styled-content> were randomized 2:1 to receive lenalidomide (25\u00a0mg\/day orally on days 1\u201321; 28\u2010day cycles) or single\u2010agent IC<\/jats:styled-content> therapy (rituximab, gemcitabine, fludarabine, chlorambucil or cytarabine). The intent\u2010to\u2010treat population comprised 254 patients (lenalidomide, n<\/jats:italic>\u00a0=\u00a0170; IC<\/jats:styled-content>, n<\/jats:italic>\u00a0=\u00a084). Subgroup analyses of PFS<\/jats:styled-content> favoured lenalidomide over IC<\/jats:styled-content> across most characteristics, including risk factors, such as high MCL<\/jats:styled-content> International Prognostic Index score, age \u226565\u00a0years, high lactate dehydrogenase (LDH<\/jats:styled-content>), stage III<\/jats:styled-content>\/IV<\/jats:styled-content> disease, high tumour burden, and refractoriness to last prior therapy. By multivariate Cox regression analysis, factors associated with significantly longer PFS<\/jats:styled-content> (other than lenalidomide treatment) included normal LDH<\/jats:styled-content> levels (P\u00a0<\/jats:italic><\u00a0<\/jats:italic>0\u00b7001), nonbulky disease (P\u00a0<\/jats:italic>=\u00a0<\/jats:italic>0\u00b7045), <3 prior antilymphoma treatments (P\u00a0<\/jats:italic>=\u00a0<\/jats:italic>0\u00b7005), and \u22656\u00a0months since last prior treatment (P\u00a0<\/jats:italic>=\u00a0<\/jats:italic>0\u00b7032). Overall, lenalidomide improved PFS <\/jats:styled-content>versus<\/jats:italic> single\u2010agent IC<\/jats:styled-content> therapy in patients with relapsed\/refractory MCL<\/jats:styled-content>, irrespective of many demographic factors, disease characteristics and prior treatment history.<\/jats:p>","DOI":"10.1111\/bjh.15025","type":"journal-article","created":{"date-parts":[[2017,11,29]],"date-time":"2017-11-29T15:41:57Z","timestamp":1511970117000},"page":"224-235","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Prospective subgroup analyses of the randomized MCL<\/scp>\u2010002 (SPRINT<\/scp>) study: lenalidomide versus<\/i> investigator's choice in relapsed or refractory mantle cell lymphoma"],"prefix":"10.1111","volume":"180","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9504-991X","authenticated-orcid":false,"given":"Luca","family":"Arcaini","sequence":"first","affiliation":[{"name":"Department of Molecular Medicine University of Pavia Pavia Italy"},{"name":"Department of Haematology Oncology Fondazione IRCCS Policlinico San Matteo Pavia Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thierry","family":"Lamy","sequence":"additional","affiliation":[{"name":"Department of Haematology H\u00f4pital Pontchaillou Rennes France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jan","family":"Walewski","sequence":"additional","affiliation":[{"name":"Department of Lymphoid Malignancies Maria Sklodowska\u2010Curie Memorial Institute and Oncology Centre Warsaw Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Belada","sequence":"additional","affiliation":[{"name":"Fourth Department of Internal Medicine, Haematology Charles University Hospital and Faculty of Medicine Hradec Kr\u00e1lov\u00e9 Czech Republic"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiri","family":"Mayer","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Haematology and Oncology University Hospital Brno Brno Czech Republic"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John","family":"Radford","sequence":"additional","affiliation":[{"name":"The University of Manchester and the Christie NHS Foundation Trust Manchester Academic Health Science Centre Manchester United Kingdom"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wojciech","family":"Jurczak","sequence":"additional","affiliation":[{"name":"Department of Haematology Jagiellonian University Medical College Krak\u00f3w Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Franck","family":"Morschhauser","sequence":"additional","affiliation":[{"name":"Department of Haematology H\u00f4pital Claude Huriez EA 7365 GRITA Lille France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julia","family":"Alexeeva","sequence":"additional","affiliation":[{"name":"Department of Haematology Research Federal Medical Research Centre Saint Petersburg Russia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8937-6351","authenticated-orcid":false,"given":"Simon","family":"Rule","sequence":"additional","affiliation":[{"name":"Department of Haematology Derriford Hospital Plymouth United Kingdom"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jos\u00e9","family":"Cabe\u00e7adas","sequence":"additional","affiliation":[{"name":"Servi\u00e7o de Anatomia Patol\u00f3gica Instituto Portugu\u00eas de Oncologia de Lisboa Francisco Gentil Lisboa Portugal"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elias","family":"Campo","sequence":"additional","affiliation":[{"name":"Haematopathology Unit, Hospital Clinic University of Barcelona Barcelona Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefano A.","family":"Pileri","sequence":"additional","affiliation":[{"name":"Unit of Haematopathology European Institute of Oncology Milan Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tsvetan","family":"Biyukov","sequence":"additional","affiliation":[{"name":"Clinical Research and Development Celgene S\u00e0rl Boudry Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Meera","family":"Patturajan","sequence":"additional","affiliation":[{"name":"Clinical Research and Development Celgene Corporation Summit NJ USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marie\u2010Laure","family":"Casadebaig Bravo","sequence":"additional","affiliation":[{"name":"Clinical Research and Development Celgene S\u00e0rl Boudry Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marek","family":"Trn\u0115n\u00fd","sequence":"additional","affiliation":[{"name":"Department of Haematology Charles University Hospital Prague Czech Republic"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"the SPRINT Trial Investigators","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2017,11,28]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-15-0488"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1999.17.4.1244"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdu264"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(15)00667-4"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2013.49.2835"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.13456"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2014.59.5363"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2009.07626.x"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.20.7977"},{"key":"e_1_2_8_11_1","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/s40164-015-0006-1","article-title":"Effect of prognostic classification on temsirolimus efficacy and safety in patients with relapsed or refractory mantle cell lymphoma: a retrospective analysis","volume":"4","author":"Hess G.","year":"2015","journal-title":"Experimental Hematology & Oncology"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-06-095331"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2013.52.2466"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(15)00559-8"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-03-635326"},{"key":"e_1_2_8_16_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdt366"}],"container-title":["British Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fbjh.15025","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bjh.15025","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,29]],"date-time":"2023-09-29T07:30:01Z","timestamp":1695972601000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/bjh.15025"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,11,28]]},"references-count":15,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2018,1]]}},"alternative-id":["10.1111\/bjh.15025"],"URL":"https:\/\/doi.org\/10.1111\/bjh.15025","archive":["Portico"],"relation":{},"ISSN":["0007-1048","1365-2141"],"issn-type":[{"type":"print","value":"0007-1048"},{"type":"electronic","value":"1365-2141"}],"subject":[],"published":{"date-parts":[[2017,11,28]]},"assertion":[{"value":"2017-07-17","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2017-09-19","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2017-11-28","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}